Literature DB >> 24818062

Markov chains and semi-Markov models in time-to-event analysis.

Erin L Abner1, Richard J Charnigo2, Richard J Kryscio3.   

Abstract

A variety of statistical methods are available to investigators for analysis of time-to-event data, often referred to as survival analysis. Kaplan-Meier estimation and Cox proportional hazards regression are commonly employed tools but are not appropriate for all studies, particularly in the presence of competing risks and when multiple or recurrent outcomes are of interest. Markov chain models can accommodate censored data, competing risks (informative censoring), multiple outcomes, recurrent outcomes, frailty, and non-constant survival probabilities. Markov chain models, though often overlooked by investigators in time-to-event analysis, have long been used in clinical studies and have widespread application in other fields.

Entities:  

Year:  2013        PMID: 24818062      PMCID: PMC4013002          DOI: 10.4172/2155-6180.S1-e001

Source DB:  PubMed          Journal:  J Biom Biostat


  16 in total

1.  Statistical methods for panel data from a semi-Markov process, with application to HPV.

Authors:  Minhee Kang; Stephen W Lagakos
Journal:  Biostatistics       Date:  2006-06-01       Impact factor: 5.899

2.  A simple stochastic model of recovery, relapse, death and loss of patients.

Authors:  E FIX; J NEYMAN
Journal:  Hum Biol       Date:  1951-09       Impact factor: 0.553

3.  The analysis of failure times in the presence of competing risks.

Authors:  R L Prentice; J D Kalbfleisch; A V Peterson; N Flournoy; V T Farewell; N E Breslow
Journal:  Biometrics       Date:  1978-12       Impact factor: 2.571

4.  The Markov process as a general method for nonparametric analysis of right-censored medical data.

Authors:  A Hillis; M Maguire; B S Hawkins; M M Newhouse
Journal:  J Chronic Dis       Date:  1986

5.  Markov models in medical decision making: a practical guide.

Authors:  F A Sonnenberg; J R Beck
Journal:  Med Decis Making       Date:  1993 Oct-Dec       Impact factor: 2.583

6.  Effects of frailty in survival analysis.

Authors:  O O Aalen
Journal:  Stat Methods Med Res       Date:  1994       Impact factor: 3.021

7.  Systematic validation of disease models for pharmacoeconomic evaluations. Swiss HIV Cohort Study.

Authors:  P P Sendi; B A Craig; D Pfluger; A Gafni; H C Bucher
Journal:  J Eval Clin Pract       Date:  1999-08       Impact factor: 2.431

8.  Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.

Authors:  Feng Pan; Jo Wern Goh; Gary Cutter; Wayne Su; Dirk Pleimes; Cheng Wang
Journal:  Clin Ther       Date:  2012-08-18       Impact factor: 3.393

9.  Mild cognitive impairment: statistical models of transition using longitudinal clinical data.

Authors:  Erin L Abner; Richard J Kryscio; Gregory E Cooper; David W Fardo; Gregory A Jicha; Marta S Mendiondo; Peter T Nelson; Charles D Smith; Linda J Van Eldik; Lijie Wan; Frederick A Schmitt
Journal:  Int J Alzheimers Dis       Date:  2012-03-25

10.  Adjusting for mortality when identifying risk factors for transitions to mild cognitive impairment and dementia.

Authors:  Richard J Kryscio; Erin L Abner; Yushun Lin; Gregory E Cooper; David W Fardo; Gregory A Jicha; Peter T Nelson; Charles D Smith; Linda J Van Eldik; Lijie Wan; Frederick A Schmitt
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.160

View more
  4 in total

1.  A comparison of time-homogeneous Markov chain and Markov process multi-state models.

Authors:  Lijie Wan; Wenjie Lou; Erin Abner; Richard J Kryscio
Journal:  Commun Stat Case Stud Data Anal Appl       Date:  2017-08-18

2.  Prospective assessment of dementia on transitions in homeboundness using multistate Markov models.

Authors:  Katherine A Ornstein; Shelley H Liu; Mohammed Husain; Claire K Ankuda; Evan Bollens-Lund; Amy S Kelley; Melissa M Garrido
Journal:  J Am Geriatr Soc       Date:  2021-12-23       Impact factor: 5.562

3.  Large socioeconomic gap in period life expectancy and life years spent with complications of diabetes in the Scottish population with type 1 diabetes, 2013-2018.

Authors:  Andreas Höhn; Stuart J McGurnaghan; Thomas M Caparrotta; Anita Jeyam; Joseph E O'Reilly; Luke A K Blackbourn; Sara Hatam; Christian Dudel; Rosie J Seaman; Joseph Mellor; Naveed Sattar; Rory J McCrimmon; Brian Kennon; John R Petrie; Sarah Wild; Paul M McKeigue; Helen M Colhoun
Journal:  PLoS One       Date:  2022-08-11       Impact factor: 3.752

4.  Model-Based Approach to Predict Adherence to Protocol During Antiobesity Trials.

Authors:  Vishnu D Sharma; François P Combes; Majid Vakilynejad; Gezim Lahu; Lawrence J Lesko; Mirjam N Trame
Journal:  J Clin Pharmacol       Date:  2017-08-31       Impact factor: 3.126

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.